Amid a conflict of interest accusation, the CDC has approved Pfizer’s and Moderna’s new bivalent COVID vaccine for 5-year-olds and up based on data from just eight mice.
“Today, CDC’s Director Rochelle P. Walensky, M.D., M.P.H., signed a decision memo expanding the use of updated (bivalent) COVID-19 vaccines to children ages 5 through 11 years. This follows the Food and Drug Administration’s (FDA) authorization of updated COVID-19 vaccines from Pfizer-BioNTech for children ages 5 through 11 years, and from Moderna for children and adolescents ages 6 through 17 years,” the CDC stated.
This vaccine decision comes amid an accusation of a conflict of interest between the CDC and Big Pharma.
Specifically, a public relations firm that represents both Pfizer and Moderna also allegedly has staff working on the CDC’s National Centre for Immunization and Respiratory Diseases (NCIRD).
“This…can’t be true. But it is. The FDA and CDC cannot be reformed, the corruption is too deep. Dismantle them entirely, and start over. #JailTime #Moderna #Pfizer
PR firm that represents Moderna sits on CDC vaccine,” tweeted Chris Martinson of Peak Prosperity.
The PR firm in question is Weber Shandwick. Paul Thacker, an investigative journalist, published the discovery in his substack. He alleged that at least one of the firm’s staffers has a role with the CDC’s NCIRD.
Weber Shandwick is reportedly the second-biggest PR firm in the world. In 2020, the firm was awarded a contract to represent the CDC.
“On his LinkedIn Account, a former Weber Shandwick employee explained that his duties at the CDC ‘focuses on boosting vaccination rates for flu, HPV, whooping cough, and COVID-19,'” stated Thacker.
The Daily Mail reports that the PR firm has been working with Pfizer since at least 2006 and Moderna since 2022.
“We are proud of the important work we do to advance public health,” Weber Shandwick told the Daily Mail.
‘When we work for organizations in the same sector, we have a thorough vetting and mitigation process to avoid conflicts, including legal review, separate and distinct teams and strong confidentiality protocols.”
The Counter Signal reached out to CDC for comment but did not receive a response by publication.
